**CONSTITUENT DRUGS**
- Ixabepilone (Ixempra)
- Capecitabine (Xeloda)

**SYNONYMS**
- IC

**USES**
- Treatment of locally advanced or metastatic breast cancer previously treated with, or resistant to, a taxane and an anthracycline
- A recommended regimen for the treatment of recurrent or metastatic breast cancer

**SUPPORTIVE CARE**

**Emetogenicity**
- Predicted: 10% to 30% (low) (see p. 518)

**Diarrhea**
- Capecitabine (see p. 522)

**Hypersensitivity**
- Ixabepilone and Capecitabine (IC) Regimen

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Administered on day(s)</th>
<th>Total dose/cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ixabepilone</td>
<td>40 mg/m²</td>
<td>IV X</td>
<td>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21</td>
<td>40 mg/m²</td>
</tr>
<tr>
<td>Capecitabine</td>
<td>2000 mg/m²</td>
<td>PO</td>
<td>X X X X X X X X X X</td>
<td>28,000 mg/m²</td>
</tr>
</tbody>
</table>

Repeated every 3 weeks

*Given as 1000 mg/m² PO twice daily.

**Myeloid Growth Factors**
- Prophylactic use not recommended (see p. 522).
- Leukopenia (grade 3 or 4): 55% to 63%
- Neutropenia
  - Grade 3 or 4: 68% to 73%
  - Febrile (grade 3 or 4): 4% to 5%

**Neurotoxicity**
- Capecitabine (see p. 523)

**TOXICITIES**

**Common (> 50%)**
- **Hematologic**
  - Leukopenia
    - Grade 3 or 4: 55% to 63%
  - Neutropenia
    - Grade 3 or 4: 68% to 73%
    - Febrile (grade 3 or 4): 4% to 5%

- **Neurologic**

Ixabepilone and Capecitabine (IC)
A Guide to Combination Cancer Chemotherapy Regimens

- Neurologic toxicity, any
  - All grades: 81%³
  - Grade 3: 19%³

Frequent (20% to 50%)
- Dermatologic
  - Hand-foot syndrome
    - Grade 3: 18% to 34%¹,³,⁴
    - Grade 3 or 4: 21%²
- Metabolic
  - Fatigue/Asthenia
    - Grade 3 or 4: 9% to 33%¹,³
- Neurologic
  - Myalgia/Arthralgia
    - Grade 3 or 4: 2% to 23%¹,³,⁴
  - Peripheral neuropathy
    - Grade 3 or 4: 23% to 26%¹,²,⁴

In frequent (5% to 19%)
- Cardiovascular
  - Dehydration
    - Grade 3 or 4: 2% to 5%¹,³
- Gastrointestinal
  - Constipation
    - Grade 3: 7%³
  - Diarrhea
    - Grade 3: 6% to 10%¹,³,⁴
    - Grade 3 or 4: 7%²
  - Nausea
    - Grade 3: 3% to 16%¹,³,⁴
  - Vomiting
    - Grade 3: 4% to 10%¹,³,⁴
- Hematologic
  - Anemia
    - Grade 3 or 4: 5% to 10%¹,²,⁴
  - Thrombocytopenia
    - Grade 3 or 4: 6% to 8%¹,²,⁴

Uncommon (1% to 4%)
- Dermatologic
  - Nail disorder
    - Grade 3: 2%¹
  - Skin exfoliation
    - Grade 3: 1%¹
  - Skin rash
    - Grade 3: 1% to 2%¹,³
- Gastrointestinal
  - Anorexia
    - Grade 3: 3%¹,³
  - Gastroesophageal reflux disease
    - Grade 3: 1%¹
  - Stomatitis/Mucositis
    - Grade 3 or 4: 2% to 4%¹,³,⁴
- Neurologic
  - Abdominal pain
    - Grade 3: 2%¹
  - Dizziness
    - Grade 3: 1%¹
  - Musculoskeletal pain
    - Grade 3: 2%¹
- Pulmonary
  - Dyspnea
    - Grade 3 or 4: 1% to 2%¹,³
- Treatment-related death
  - Neutropenia-related toxicity: 3%¹
  - Neutropenia-related toxicity with liver dysfunction at baseline: 1%¹

RECOMMENDED LABORATORY TESTS

Baseline
- AST/ALT
- Total bilirubin
- Serum creatinine
- CBC with differential

Prior to Each Treatment
- AST/ALT
- Total bilirubin
- Serum creatinine
- CBC with differential

Recommended Pretreatment Values
- ANC
  - A pretreatment ANC of 1,000 cells/mcL is usually considered acceptable for treatment.
- Platelets
  - A pretreatment platelet count of 75,000 cells/mcL is usually considered acceptable for treatment.

DOSAGE MODIFICATIONS

Renal Function (see p. 526)

Liver Function (see p. 531)
- Reduce ixabepilone by 20% for AST or ALT >2.5 times ULN and ≤ 10 times ULN and bilirubin ≤ 1.5 times ULN.⁸
- Reduce ixabepilone by 25% to 50% for AST or ALT > 2.5 times ULN and ≤ 10 times ULN and bilirubin > 1.5 to 3 times ULN.⁸
- Omit ixabepilone for AST or ALT > 10 times ULN or bilirubin > 3 times ULN.⁸

REFERENCES
1. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus...


